Who are Odalasvir 25 mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EBR/GZR (elbasvir/grazoprevir), EBR/GZR, BMS-790052 (Daclatasvir), Mavyret, PIBRENTASVIR, Zepatier.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/odalasvir-25-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Odalasvir 25 mg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Odalasvir 25 mg (Odalasvir 25 mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA); NS5A inhibitor. Area: Infectious Disease.

discontinued Direct-acting antiviral (DAA); NS5A inhibitor Hepatitis C virus NS5A protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Odalasvir 25 mg (Odalasvir 25 mg) — Janssen Research & Development, LLC. Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Odalasvir 25 mg TARGET	Odalasvir 25 mg	Janssen Research & Development, LLC	discontinued	Direct-acting antiviral (DAA); NS5A inhibitor	Hepatitis C virus NS5A protein
EBR/GZR (elbasvir/grazoprevir)	EBR/GZR (elbasvir/grazoprevir)	University of Florida	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	Hepatitis C virus NS5A protein and NS3/4A serine protease
EBR/GZR	EBR/GZR	Dallas VA Medical Center	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	Hepatitis C virus NS5A protein and NS3/4A serine protease
BMS-790052 (Daclatasvir)	BMS-790052 (Daclatasvir)	Bristol-Myers Squibb	phase 3	NS5A inhibitor	Hepatitis C virus NS5A protein
Mavyret	GLECAPREVIR	AbbVie	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
PIBRENTASVIR	PIBRENTASVIR		marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
Zepatier	ELBASVIR	Merck & Co.	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-24 — Zepatier · 7973040 · US
2030-06-10 — Mavyret · 10039754 · US
2030-06-10 — Mavyret · 10028937 · US
2030-11-06 — Mavyret · 9586978 · US
2030-12-10 — Mavyret · 10039754*PED · US
2030-12-10 — Mavyret · 10028937*PED · US
2031-05-04 — Zepatier · 8871759 · US
2031-05-06 — Mavyret · 9586978*PED · US
2032-01-19 — Mavyret · 8648037 · US
2032-05-18 — Mavyret · 8937150 · US
2032-07-19 — Mavyret · 8648037*PED · US
2032-11-18 — Mavyret · 8937150*PED · US
2034-03-14 — Mavyret · 11484534 · US
2034-03-14 — Mavyret · 10286029 · US
2034-09-14 — Mavyret · 10286029*PED · US
2034-09-14 — Mavyret · 11484534*PED · US
2035-05-08 — Mavyret · RE48923 · US
2035-06-05 — Mavyret · 9321807 · US
2035-11-08 — Mavyret · RE48923*PED · US
2035-12-05 — Mavyret · 9321807*PED · US
2036-06-24 — Mavyret · 11246866 · US
2036-12-24 — Mavyret · 11246866*PED · US

Sponsor landscape (Direct-acting antiviral (DAA); NS5A inhibitor class)

Janssen Research & Development, LLC · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Odalasvir 25 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/odalasvir-25-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab